<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19317">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855411</url>
  </required_header>
  <id_info>
    <org_study_id>B1701019</org_study_id>
    <secondary_id>POC</secondary_id>
    <nct_id>NCT02855411</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)</brief_title>
  <official_title>A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether PF-04958242 is safe and effective in the
      treatment of cognitive dysfunction in schizophrenia subjects
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not
    due to any safety concern or change in benefit:risk assessment.
  </why_stopped>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the MCCB (MATRICS Consensus Cognitive Battery) working memory domain to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the UPSA-VIM (University of California, San Diego (UCSD) Performance Based Skills Assessment - Validation of Intermediate Measures) to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment and Rating of Ataxia (SARA)</measure>
    <time_frame>baseline, Weeks 2, 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>baseline, followed by weekly (Weeks 1 throughout 12), and 28 days after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the MCCB Neurocognitive composite (excludes Social Cognition Domain) to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MCCB overall composite (includes all 7 domains) to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in each of the 6 individual MCCB Domain scores (excludes MCCB Working Memory) to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the SCI-PANSS (Structured Clinical Interview Positive and Negative Symptoms Scale) total to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the SCI-PANSS Positive, Negative and General Psychopathology subscales to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the CGI-S (Clinical Global Impression-Severity) to Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I (Clinical Global Impression-Improvement) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cognitive Impairment Associated With Schizophrenia (CIAS)</condition>
  <arm_group>
    <arm_group_label>0.15 mg PF-04958242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg PF-04958242</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04958242</intervention_name>
    <description>0.15 mg or 0.5 mg, twice daily (BID) for 12 weeks, capsule</description>
    <arm_group_label>0.15 mg PF-04958242</arm_group_label>
    <arm_group_label>0.5 mg PF-04958242</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo, twice daily (BID) for 12 weeks, capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy male and/or female subjects between the ages of 18 and 50 years,
             inclusive, with Diagnostic Statistical Manual of Mental Disorders, Fifth Edition
             (DSM-5) diagnosis of schizophrenia of at least 2 years duration as confirmed by the
             M.I.N.I 7.0 for Psychotic Disorders

          -  Evidence of stable schizophrenia symptomatology &gt;=3 months (ie, no hospitalizations
             for schizophrenia, no increase in level of psychiatric care due to worsening of
             symptoms of schizophrenia).

          -  Subjects must be in ongoing maintenance atypical antipsychotic therapy (except
             clozapine), on a stable treatment regimen for &gt;=2 months prior to Baseline/Day 1,
             including concomitant psychotropic treatments. Subjects should be on no more than 2
             background antipsychotics.

          -  Subject must have an identified informant

          -  Subject must reside in a stable living situation for at least 12 weeks prior to
             Screening.

        Exclusion Criteria:

          -  Subjects with a current DSM-5 diagnosis of schizoaffective disorder in the judgment
             of the investigator.

          -  Subjects with a current DSM-5 diagnosis of major depressive episode, manic and
             hypomanic episode, panic disorder, agoraphobia, social anxiety disorder,
             obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety
             disorder on the M.I.N.I 7.0 for Psychotic Disorders or in the judgment of the
             investigator.

          -  Subjects with a lifetime DSM-5 diagnosis of antisocial personality disorder, anorexia
             nervosa, bulimia nervosa, binge-eating disorder on the M.I.N.I 7.0 for Psychotic
             Disorders or in the judgment of the investigator.

          -  Subjects who meet the DSM-5 diagnosis of moderate or severe psychoactive substance
             use disorder (excluding nicotine dependence) within 12 months of screening on the
             M.I.N.I 7.0 for Psychotic Disorders interview and as determined by the investigator.

          -  Subjects with significant extrapyramidal symptoms which have not been stabilized with
             anticholinergics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC (Investigator Site File Location)</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excell Research, Inc</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Institute, LLC (CNRI-San Diego, LLC)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center For Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Centers for Psychiatric Research</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinmay K. Patel, D.O.</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide, LLC</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Strategies of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research, LLC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1701019&amp;StudyName=A%2012%20Week%2C%20Phase%202a%2C%20Randomized%2C%20Double-blind%2C%20Placebo%20Controlled%2C%20Parallel%20Group%20Study%20To%20Evaluate%20The%20Safety%20And%20Efficacy%20Of%20Pf-04958242%20In%20Subjects%20With%20Cognitive%20Impairment%20Associated%20With%20Schizophrenia%20%28cias%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1701019&amp;StudyName=A+12+Week%2C+Phase+2%2C+Randomized%2C+Double-blind%2C+Placebo+Controlled%2C+Parallel+Group+Study+To+Evaluate+The+Safety+And+Efficacy+Of+Pf-04958242+In+Subjects+With+Cognitive+Impairment+Associated+With+Schizophrenia+%28cias%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>July 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
